Competitor Landscape: Graft Versus Host Disease (GVHD)
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharma’s view of the disease landscape
Landscape Updates: ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved product’s lifecycle management initiatives; ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies
Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
Scope
The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher – these are outlined in the report Appendix
Forecasts are presented in pipeline forecast figures & detailed tables
‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided
Key Highlights
Anticipated approval of ATIR101 is delayed both in the EU and US – with the postponed primary completion date in the ongoing Phase III trial delaying the expected US approval by 9 months
If approved, Ruxolitinib for use in combination with corticosteroids for the treatment of steroid-refractory aGVHD would make it the second drug to receive US approval for the treatment of GVHD after Janssen/AbbVie’s IBR
Incyte has not only delayed the initiation of Itacitinib's GRAVITAS-309 trial, but significantly extended its duration (from ~2.5 years to ~4.5 years)
Reasons to Buy
Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
Reviews ongoing lifecycle management strategies for existing players in the market
A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts
AbGenomics
Actelion
Adienne
Alexion
Amgen
Bellicum Pharmaceuticals
BMS
Cynata
CytoDyn
Eli Lilly
ElsaLys Biotech
Fate Therapeutics
Genentech
Generon
Gilead
GSK
Incyte
ITC
Janssen
Jazz Pharmaceuticals
Kadmon
Kalytera
Kamada
Kiadis
Mallinckrodt
Medsenic
Novartis
Ocugen
OncoImmune
Pluristem
RegImmune
Rigel Pharmaceuticals
Roche
Syndax
Takeda
TALENT Biotech
Xenikos
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.